PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer

Overview

This clinical trial studies positron emission tomography (PET)/computed tomography (CT) and lymph node mapping in finding lymph node metastasis in patients with endometrial cancer that is at high risk of spreading. A PET/CT scan is a procedure that combines the pictures from a PET scan and a CT scan, which are taken at the same time from the same machine. The combined scans give more detailed pictures of areas inside the body than either scan gives by itself. Lymph node mapping uses a radioactive dye, called indocyanine green solution, to identify lymph nodes that may contain cancer cells. PET/CT and sentinel lymph node mapping may be better ways than surgery to identify cancer in the lymph nodes.

Full Title of Study: “Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 30, 2020

Detailed Description

PRIMARY OBJECTIVES:

I. To estimate the false negative rate of PET/CT and/or sentinel lymph node mapping in the detection of positive lymph nodes in women with high risk endometrial cancers.

SECONDARY OBJECTIVES:

I. To estimate the sensitivity, specificity, positive predictive value, and negative predictive value of PET/CT and/or sentinel lymph node mapping in the detection of positive lymph nodes in women with high risk endometrial cancer.

II. To determine if a molecular panel of estrogen-induced genes that we have previously identified from retrospective studies correlate with extra-uterine spread including lymph node metastasis at the time of surgical staging for endometrial cancer.

III. To prospectively identify patterns of lymphatic spread of endometrial cancer.

IV. To correlate cancer antigen 125 (CA-125) and WAP four-disulfide core domain 2 (HE4) levels with disease metastasis at the time of surgical staging and to explore the use of other serum biomarkers to predict recurrence.

V. To prospectively collect morbidity and mortality data related to performing lymph node dissection including intra-operative and postoperative complications.

VI. To determine whether metabolic parameters of the primary endometrial tumor on PET including tumor intensity (maximum standard uptake value [SUV] and peak SUV), metabolic tumor volume (obtained at a threshold of 40% of maximum and at a threshold of SUV=3), and total lesion glycolysis (expressed average SUV over the metabolic tumor volume) are predictive of locoregional or metastatic spread, and whether these parameters correlate with CA-125 and HE4 levels.

OUTLINE:

Patients undergo PET/CT prior to surgery. Patients then undergo intraoperative lymph node mapping with indocyanine green solution, given via superficial and deep cervical injection during full lymphadenectomy.

Interventions

  • Procedure: Computed Tomography
    • Undergo PET/CT
  • Drug: Indocyanine Green Solution
    • Given via superficial and deep cervical injection
  • Other: Laboratory Biomarker Analysis
    • Correlative studies
  • Procedure: Lymph Node Mapping
    • Undergo lymph node mapping
  • Procedure: Lymphadenectomy
    • Undergo full lymphadenectomy
  • Procedure: Positron Emission Tomography
    • Undergo PET/CT

Arms, Groups and Cohorts

  • Experimental: Diagnostic (PET/CT, lymph node mapping)
    • Patients undergo PET/CT prior to surgery. Patients then undergo intraoperative lymph node mapping with indocyanine green solution, given via superficial and deep cervical injection during full lymphadenectomy.

Clinical Trial Outcome Measures

Primary Measures

  • False negative rate of positron emission tomography (PET)/computed tomography (CT)
    • Time Frame: Baseline
    • Compared with pathological findings as the gold standard. The false negative rate for the procedure and for the combination of the 2 procedures will be estimated with 90% credible intervals. The posterior probability that the false negative rate is > 10% for each procedure and for the combination of the 2 procedures will also be reported.
  • False negative rate of sentinel lymph node mapping
    • Time Frame: At time of surgery
    • Compared with pathological findings as the gold standard. The false negative rate for the procedure and for the combination of the 2 procedures will be estimated with 90% credible intervals. The posterior probability that the false negative rate is > 10% for each procedure and for the combination of the 2 procedures will also be reported.

Secondary Measures

  • Concordance for each procedure and for the combination of both procedures
    • Time Frame: At time of surgery
    • The concordance for each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.
  • Sensitivity of each procedure and for the combination of both procedures
    • Time Frame: At time of surgery
    • The sensitivity of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.
  • Specificity of each procedure and for the combination of both procedures
    • Time Frame: At time of surgery
    • The specificity of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.
  • Positive predictive value (PPV) of each procedure and for the combination of both procedures
    • Time Frame: At time of surgery
    • The PPV of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.
  • Negative predictive value (NPV) of each procedure and for the combination of both procedures
    • Time Frame: At time of surgery
    • The NPV of each procedure and for the combination of the 2 procedures will be estimated with 95% confidence intervals using pathologic findings as the gold standard.
  • CA-125 levels
    • Time Frame: Baseline
    • Logistic regression methods will be used to model the logit of the probability of metastatic disease at the time of surgical staging as a function of CA-125 level, HE4 level, and other metabolic parameters including tumor intensity, metabolic tumor volume, and total lesion glycolysis. The odds ratio of the association between these factors and metastatic disease will be estimated with a 95% confidence interval. The logit of the probability of locoregional spread as a function of these factors will be similarly modeled. The correlations among these factors will also be estimated.
  • HE4 levels
    • Time Frame: Baseline
    • Logistic regression methods will be used to model the logit of the probability of metastatic disease at the time of surgical staging as a function of CA-125 level, HE4 level, and other metabolic parameters including tumor intensity, metabolic tumor volume, and total lesion glycolysis. The odds ratio of the association between these factors and metastatic disease will be estimated with a 95% confidence interval. The logit of the probability of locoregional spread as a function of these factors will be similarly modeled. The correlations among these factors will also be estimated.
  • Metabolic parameters
    • Time Frame: Baseline
    • Logistic regression methods will be used to model the logit of the probability of metastatic disease at the time of surgical staging as a function of CA-125 level, HE4 level, and other metabolic parameters including tumor intensity, metabolic tumor volume, and total lesion glycolysis. The odds ratio of the association between these factors and metastatic disease will be estimated with a 95% confidence interval. The logit of the probability of locoregional spread as a function of these factors will be similarly modeled. The correlations among these factors will also be estimated.
  • Incidence of intra-operative complications
    • Time Frame: At time of surgery
    • Morbidity and mortality data will be tabulated, including intra-operative complications.
  • Incidence of post-operative complications
    • Time Frame: At time of surgery
    • Morbidity and mortality data will be tabulated, including post-operative complications.

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically confirmed high grade endometrial cancer including grade 3 endometroid, serous, clear cell, malignant mixed Mullerian tumor (MMMT) or any mixed tumor containing one of these cell types
  • Patients with a grade 1/2 tumors and evidence of deep myometrial invasion or cervical involvement on preoperative imaging or physical exam
  • Candidate for surgery
  • No evidence of peritoneal disease on preoperative imaging
  • Negative pregnancy test if of child-bearing age
  • No preoperative treatment for endometrial cancer including radiation or chemotherapy
  • Previous hormonal therapy is allowed

Exclusion Criteria

  • Medical co-morbidities making surgery unsafe, as determined by the primary treating physician
  • Any contraindications to PET/CT or lymph node mapping (inability to control serum glucose to a value of =< 200 mg/dl for fludeoxyglucose F-18 [FDG]-PET/CT)
  • Does not meet histologic criteria
  • Evidence of peritoneal or distant metastasis on preoperative imaging
  • Baseline creatinine (necessary for imaging studies)

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • M.D. Anderson Cancer Center
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pamela Soliman, Principal Investigator, M.D. Anderson Cancer Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.